Association of CDC25 phosphatase family polymorphisms with the efficacy/toxicity of platinum-based chemotherapy in Chinese advanced NSCLC patients

被引：6

作者：

Cai, Weijing ^{[1
]}

Chen, Chang ^{[2
]}

Li, Xinzheng ^{[3
]}

Shi, Jinyun ^{[4
]}

Sun, Qian ^{[1
]}

Liu, Di ^{[1
]}

Sun, Yifeng ^{[2
]}

Hou, Likun ^{[5
]}

Zhao, Xueying ^{[6
,7
]}

Gu, Shaohua ^{[6
,7
]}

Wu, Qihan ^{[8
]}

Chen, Hongyan ^{[6
,7
]}

Zhang, Wei ^{[9
]}

Jin, Li ^{[6
,7
]}

Lu, Daru ^{[6
,7
]}

Fei, Ke ^{[2
]}

Su, Bo ^{[1
]}

Qian, Ji ^{[6
,7
]}

机构：

[1] Tongji Univ, Sch Med, Cent Lab, Shanghai Pulm Hosp, Shanghai 200433, Peoples R China

[2] Tongji Univ, Sch Med, Dept Thorac Surg, Shanghai Pulm Hosp, Shanghai 200433, Peoples R China

[3] Shanxi Canc Hosp, Dept Breast Canc, Taiyuan, Peoples R China

[4] Tongji Univ, Sch Med, Dept Med Imaging, Shanghai Pulm Hosp, Shanghai 200433, Peoples R China

[5] Tongji Univ, Sch Med, Dept Pathol, Shanghai Pulm Hosp, Shanghai 200433, Peoples R China

[6] Fudan Univ, Shanghai Canc Ctr, State Key Lab Genet Engn, Shanghai 200433, Peoples R China

[7] Fudan Univ, Sch Life Sci, MOE Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China

[8] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China

[9] Shanghai Jiao Tong Univ, Dept Resp Dis, Shanghai Chest Hosp, Shanghai 200030, Peoples R China

来源：

FUTURE ONCOLOGY | 2014年 / 10卷 / 07期

关键词：

CDC25; family; chemotherapy; lung cancer; platinum; single nucleotide polymorphism; CELL LUNG-CANCER; III BETA-TUBULIN; DNA-REPAIR; EXPRESSION; ERCC1; PROGNOSIS; MARKER; GENES; RRM1;

D O I：

10.2217/fon.14.25

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To explore relationships between single nucleotide polymorphisms (SNPs) of the CDC25 protein family and the survival and chemotherapy responses of patients with advanced non-small-cell lung cancer (NSCLC). Methods & materials: We genotyped 14 SNPs of the CDC25 family in 663 Chinese patients with advanced NSCLC who were treated with first-line platinum-based chemotherapy and, in evaluable patients, analyzed relationships between the CDC25 family and the efficacy of platinum-based chemotherapy. Results:CDC25A rs3731513 and rs1380053, CDC25C rs6861656, CDC25A haplotype T/A/A/A/C and CDC25C haplotype A/G/G/G/C were significantly associated with the patients' progression-free survival. In addition, CDC25B rs3761218 and haplotype G/T/G/G were associated with the occurrence of severe toxicity with platinum-based chemotherapy, especially gastrointestinal and hematological toxicity. Conclusion: These findings reveal a relationship between genetic variations of the CDC25 family and the efficacy and toxicity of platinum-based chemotherapy in patients with advanced NSCLC, especially in those with non-squamous-cell carcinoma.

引用

页码：1175 / 1185

页数：11

共 50 条

[41] Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients [J].

Sun, Xinchen ;

Li, Fan ;

Sun, Ning ;

Qin Shukui ;

Chen Baoan ;

Feng Jifeng ;

Lu, Cheng ;

Lu Zuhong ;

Cheng Hongyan ;

Cao YuanDong ;

Ji Jiazhong ;

Zhou Yingfeng .

LUNG CANCER, 2009, 65 (02) :230-236

[42] Correlation between miR-138-5p expression and efficacy of platinum-based chemotherapy in advanced gastric cancer patients [J].

Ning, Jie ;

Jiao, Yang ;

Deng, Xuefei ;

Liu, Wei ;

Xie, Xiaoque ;

Zhang, Yiyin ;

Zhao, Chenchen ;

Ma, Tai ;

Gu, Kangsheng .

TRANSLATIONAL CANCER RESEARCH, 2020, 9 (01) :145-154

[43] DNA Repair Capacity in Peripheral Blood Lymphocytes Predicts Efficacy of Platinum-based Chemotherapy in Patients with Gastric Cancer [J].

Zhang, Yi-Yin ;

Gu, Kang-Sheng .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (09) :5507-5512

[44] Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy [J].

Helbekkmo, Nina ;

Aasebo, Ulf ;

Sundstrom, Stein H. ;

von Plessen, Christian ;

Brunsvig, Paal Fr. ;

Bremnes, Roy M. .

LUNG CANCER, 2008, 62 (02) :253-260

[45] Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy [J].

Zou, Ting ;

Liu, Jun-Yan ;

Qin, Qun ;

Guo, Jie ;

Zhou, Wen-Zhi ;

Li, Xiang-Ping ;

Zhou, Hong-Hao ;

Chen, Juan ;

Liu, Zhao-Qian .

BIOMEDICINES, 2023, 11 (12)

[46] Association Between Polymorphisms of ERCC1 and XPD and Clinical Response to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer [J].

Li, Fan ;

Sun, Xinchen ;

Sun, Ning ;

Qin, Shukui ;

Cheng, Hongyan ;

Feng, Jifeng ;

Chen, Baoan ;

Cheng, Lu ;

Lu, Zuhong ;

Ji, Jiazhong ;

Zhou, Yingfeng .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (05) :489-494

[47] ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer [J].

Barba, Andres ;

Lopez-Vilaro, Laura ;

Ferre, Malena ;

Majem, Margarita ;

Martinez-Recio, Sergio ;

Bell, Olga ;

Arranz, Maria J. ;

Salazar, Juliana ;

Sullivan, Ivana .

PHARMACEUTICS, 2024, 16 (09)

[48] Efficacy and safety of non-platinum based doublets chemotherapy compared with platinum-based doublets chemotherapy in advanced non-small-cell lung cancer (NSCLC): a meta-analysis [J].

Huang, Jing-Tao ;

Zhang, Zhong-Wei ;

Zhang, Yong-Min ;

Yan, Wen-Qiang ;

Li, Zhi-Gang .

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (08) :15262-15273

[49] Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology [J].

Minato, Akinori ;

Murooka, Kazuki ;

Okumura, Yutaka ;

Takaba, Tomohisa ;

Higashijima, Katsuyoshi ;

Nagata, Yujiro ;

Tomisaki, Ikko ;

Harada, Kenichi ;

Fujimoto, Naohiro .

IN VIVO, 2024, 38 (02) :873-880

[50] Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy [J].

Zheng, Yi ;

Deng, Zheng ;

Tang, Mimi ;

Cai, Pei .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (04) :495-502

← 1 2 3 4 5 →